Key result
mRNA-based COVID-19 vaccine booster doses restore waning immunity and reduce the incidence and severity of COVID-19, though their global rollout faces challenges regarding equitable access and rare adverse events.
Why the study?
COVID-19 booster programs were expanding despite a lack of robust evidence on effectiveness, safety, frequency, optimal timing, and eligibility criteria.
What are the benefits and risks of offering frequent mRNA-based COVID-19 vaccine booster doses?
What are the benefits and risks of offering frequent mRNA-based COVID-19 vaccine booster doses?
This mini-review discusses the ethical and clinical implications of COVID-19 mRNA vaccine booster programs, highlighting the lack of robust evidence on optimal timing and frequency.
The number of COVID-19 vaccine-rich countries that have started COVID-19 third-dose booster programs is growing dramatically despite the lack of robust evidence on the effectiveness, safety, and frequency of the required booster doses that makes the individuals/populations immune to COVID -19 infection. Beyond the ethical dilemma, the scarcity of studies on the optimal timing for offering booster doses, eligibility criteria, and if there is any association between premature or delayed administration and the degree of protection against infection. The aim of this mini- review was to collect and analyze published data on this topic in a trial to answer some questions related to the benefits versus the risks of offering frequent boosters of mRNA vaccines for increasing the population immunity against COVID-19 infection considering the current policy of providing SARS-CoV-2 vaccine booster doses in rich countries versus those in relatively poor countries with limited access to vaccination. (www.actabiomedica.it).
No takes yet. Share an insight, caveat, or question.
Nashwan et al. (2022) conducted a review in COVID-19. mRNA-based COVID-19 Vaccines Booster Dose was evaluated. mRNA-based COVID-19 vaccine booster doses restore waning immunity and reduce the incidence and severity of COVID-19, though their global rollout faces challenges regarding equitable access and rare adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: